BioCentury
ARTICLE | Clinical News

Ganaxolone: Phase III data

June 20, 2016 7:00 AM UTC

Marinus said it will discontinue development of ganaxolone to treat focal onset seizures after top-line data from a double-blind, international Phase III trial in 359 adults epileptics with drug-resis...